Squarepoint
GTHX

Squarepoint’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Squarepoint’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-105,156
Closed -$454K – 4788
2024
Q1 		$454K Buy
105,156
+88,938
+548% +$310K ﹤0.01% 3115
2023
Q4 		$49.5K Buy
16,218
+3,403
+27% +$6.39K ﹤0.01% 3851
2023
Q3 		$18.5K Buy
+12,815
New +$24.8K ﹤0.01% 3701
2023
Q2 		– Sell
-27,455
Closed -$73.6K – 4126
2023
Q1 		$73.6K Sell
27,455
-21,859
-44% -$105K ﹤0.01% 3020
2022
Q4 		$268K Buy
49,314
+1,133
+2% +$9.49K ﹤0.01% 2631
2022
Q3 		$602K Buy
48,181
+27,255
+130% +$311K ﹤0.01% 2112
2022
Q2 		$103K Buy
20,926
+8,607
+70% +$47.7K ﹤0.01% 2615
2022
Q1 		$94K Sell
12,319
-2,520
-17% -$23.9K ﹤0.01% 2607
2021
Q4 		$152K Buy
+14,839
New +$189K ﹤0.01% 2812
2021
Q3 		– Sell
-9,332
Closed -$205K – 3559
2021
Q2 		$205K Buy
+9,332
New +$207K ﹤0.01% 2813
2021
Q1 		– Sell
-11,919
Closed -$214K – 3730
2020
Q4 		$214K Sell
11,919
-92,549
-89% -$1.38M ﹤0.01% 2464
2020
Q3 		$1.21M Buy
104,468
+83,308
+394% +$1.38M 0.02% 895
2020
Q2 		$513K Sell
21,160
-33,924
-62% -$561K 0.01% 1305
2020
Q1 		$607K Buy
55,084
+35,466
+181% +$662K 0.02% 934
2019
Q4 		$519K Sell
19,618
-13,253
-40% -$310K ﹤0.01% 1758
2019
Q3 		$749K Buy
32,871
+26,067
+383% +$822K 0.01% 1411
2019
Q2 		$209K Buy
+6,804
New +$143K ﹤0.01% 2094
2019
Q1 		– Sell
-62,233
Closed -$1.19M – 2500
2018
Q4 		$1.19M Buy
62,233
+31,498
+102% +$1.18M 0.01% 852
2018
Q3 		$1.61M Buy
30,735
+12,435
+68% +$678K 0.02% 799
2018
Q2 		$795K Buy
+18,300
New +$784K 0.01% 982

Other funds holding GTHX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Squarepoint's GTHX Position: Q2 2024 in Review

Squarepoint sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2024, closing a stake of 105,156 shares — an estimated $454K sold.

Squarepoint first reported a position in GTHX in Q2 2018 and held it in 20 quarters. The position peaked at $1.61M in Q3 2018. 88 funds tracked by Wall St. Rank hold GTHX as of Q2 2024.

  • Squarepoint reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Squarepoint sold 105,156 G1 Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $454K.
  • Squarepoint first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2018 and held it in 20 quarters.
  • Squarepoint's G1 Therapeutics, Inc. Common Stock position peaked at $1.61M in Q3 2018.
  • 88 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Squarepoint's 13F filing for Q2 2024, filed 14 Aug 2024.